Cyberpunk 2077 has come a long way. After facing multiple delays and a rocky launch in 2020, many thought it might spell the end for CD Projekt Red, the developers best known for The Witcher 3: The ...

While the initial showing of Cyberpunk 2077 during the Nintendo Direct did not use DLSS at all, CD Projekt RED has confirmed that the game will use the technology on launch. In a statement to ...

TL;DR: Cyberpunk 2077 on Nintendo Switch 2 utilizes NVIDIA DLSS to deliver streamlined gameplay in all modes. Cyberpunk 2077 will leverage NVIDIA DLSS to help scale and run the game at on the ...

One of the most ambitious titles lined up for the launch of the Nintendo Switch 2, CD Projekt RED's Cyberpunk 2077 has been showcased via work-in-progress code seen at the console's launch tour.

As reported by Digital Foundry for Eurogamer, the studio made this statement when asked about use of DLSS on Cyberpunk 2077 on the Switch 2: “We’re using a version of DLSS available for ...

The Switch 2 version of Cyberpunk 2077 certainly doesn't match up to PS5, but that it runs Phantom Liberty at all is impressive. Cyberpunk 2077: Ultimate Edition is the first Switch 2 game that’s been ...

So many PlayStation 5 and Xbox Series X games are viable for Switch 2 ports (CD Projekt) The use of DLSS in the Nintendo Switch 2 version of Cyberpunk 2077 has been confirmed, as the port becomes ...

CD Projekt RED has confirmed to Digital Foundry that the Switch 2 launch title, Cyberpunk 2077: Ultimate Edition, will make use of DLSS, Nvidia's AI-powered upscaling system. "We're using a ...

Finally, PC resource management sees optimization tools that reduce storage bloat when updating . Although not part of 2.3, Kuro Games teased a full‑scale collaboration with Cyberpunk: Edgerunners, ...

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new ...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US – its fourth bolt-on deal of 2021. South San Francisco-based Amunix specialises ...